Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Many thanks Wallyj for all the notes.
August 2, 2021 - Canadian Overseas Petroleum Limited ("COPL" or the "Company") (CSE: XOP) & (LSE: COPL), an international oil and gas exploration and development company, today announces that is has requested a temporary Management Cease Trade Order ("MCTO") from the Alberta Securities Commission ("ASC") in connection with the Company's filing of its unaudited interim financial statements and the applicable CEO and CFO certifications in respect of such filings for the period ended June 30, 2021 (collectively the "Interim Filings").
The Company completed its acquisition of Atomic Oil and Gas LLC ("Atomic") and Southwestern Production Corp. on March 16, 2021 (the "Acquisition"). The Company is working to file a prospectus with the London Stock Exchange detailing the Acquisition, which constituted a reverse takeover pursuant to the United Kingdom Listing Rules, in advance of the Interim Filings. Due to the foregoing proceedings, the Company will be delayed in respect of preparing the Interim Filings. The Company is requesting the MCTO in order to secure additional time for the Company to prepare the interim financial statements for the period ended June 30, 2021.
Accordingly, the Company has applied to the ASC for the MCTO that will prohibit the management of the Company from trading in the securities of the Company until such time as the Interim Filings are filed. No decision has yet been made by the ASC on this application. The ASC may grant the application and issue the MCTO or it may impose an issuer cease trade order if the Interim Filings are not filed in a timely fashion.
The Company notes that:
The Company is required to file its Interim Filings by August 16, 2021 (the "Filing Deadline"), as required pursuant to National Instrument 51-102 - Continuous Disclosure Obligations. At this time the Company is uncertain as to whether it will be able to complete its Interim Filings on or before the Filing Deadline.
The Company is working diligently to prepare and file the Interim Filings, on or before August 31, 2021.
The Company confirms that, other than as disclosed in prior press releases, there is no material information concerning the affairs of the Company that has not been generally disclosed since the filing on July 23, 2021 of the Company's latest interim financial reports for the period ended March 31, 2021.
Until the Company has filed the Interim Filings, members of the Company's management and other insiders are subject to an insider trading black-out.
During the period of default and until filing of the Interim Filings, the Company intends to satisfy the provisions of the alternative information guidelines as required by National Policy 12-203 Management Cease Trade Orders.
No SP
Have my Allocation with IWeb. But not showing any with H&L.
Great opportunity to buy millions of shares today if you want a bigger slice.
Fri, 11th Jun 2021 07:00
RNS Number : 5656B
Open Orphan PLC
11 June 2021
11 June 2021
Open Orphan plc
("Open Orphan", the "Company")
Exercise of Warrants
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has received notice of exercise of warrants by investors, who participated in the Venn loan note financing in December 2018, over 404,806 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") at a price of 0.1 pence per share for 143,312 Ordinary Shares and at a price of 2.2 pence per share for 261,494 Ordinary Shares. The gross proceeds of this exercise received by the Company amount to £5,896.18.
Following this exercise, the warrants issued to investors in connection with the 2018 Venn loan note have been substantially exercised with only the Chairman's 657,285 warrants outstanding.
The total outstanding warrants over Ordinary Shares are as follows:
Number of Ordinary Shares
Exercise Price per share
Date awarded
Expiry Date
Beneficiary
232,696
0.1 pence
11 December 2018
10 December 2023
Venn loan note investor
424,589
2.2 pence
11 December 2018
10 December 2023
Venn loan note investor
1,607,142
5.6 pence
28 June 2019
27 June 2024
An advisor
The Company has made application for 404,806 new Ordinary Shares, to be issued and allotted as a result of the warrant exercise set out above, to be admitted to trading on AIM and Euronext Growth. Admission is expected to occur at 8.00 a.m. on 16 June 2021.
Total Voting Rights
Following the admission of the 404,806 new Ordinary Shares, the Company's total issued ordinary share capital will consist of 670,855,002 Ordinary Shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.
If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com.